Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.
暂无分享,去创建一个
Ayman El-Kattan | C. Loi | A. El‐Kattan | Cho-Ming Loi | Susan Hurst | J. Brodfuehrer | Joanne Brodfuehrer | Susan I. Hurst | S. Hurst
[1] T. Kararli. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.
[2] Leslie Z. Benet,et al. Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat , 1998, Pharmacology.
[3] M. Shimada,et al. Isolation and Characterization of a New Major Intestinal CYP3A Form, CYP3A62, in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.
[4] O. Pelkonen,et al. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. , 2006, Current drug metabolism.
[5] J. Goldstein,et al. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.
[6] Mary F Paine,et al. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.
[7] Younggil Kwon,et al. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists , 2001, Springer US.
[8] F. Gonzalez,et al. The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.
[9] I R Rowland,et al. In vivo and in vitro models of the human colonic flora. , 1992, Critical reviews in food science and nutrition.
[10] Barry C. Jones,et al. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.
[11] E. Warner,et al. Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] W. L. Chiou. New perspectives on the theory of permeability and resistance in the study of drug transport and absorption , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[13] C. Nyström,et al. Dissolution rate measurements of sparingly soluble compounds with the Coulter Counter model TAII § , 1985, The Journal of pharmacy and pharmacology.
[14] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[15] A. Li,et al. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. , 2001, Chemico-biological interactions.
[16] C. Porter,et al. The Lymph Lipid Precursor Pool Is a Key Determinant of Intestinal Lymphatic Drug Transport , 2006, Journal of Pharmacology and Experimental Therapeutics.
[17] M. Otsuka,et al. Pharmaceutical Evaluation of Carbamazepine Modifications: Comparative Study for Photostability of Carbamazepine Polymorphs by using Fourier‐transformed Reflection‐absorption Infrared Spectroscopy and Colorimetric Measurement , 1994, The Journal of pharmacy and pharmacology.
[18] M. Másson,et al. Cyclodextrins and drug permeability through semi-permeable cellophane membranes. , 2002, International journal of pharmaceutics.
[19] S. Wrighton,et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.
[20] Michael B. Bolger,et al. The composite solubility versus pH profile and its role in intestinal absorption prediction , 2008, AAPS PharmSci.
[21] K. Beaumont,et al. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. , 2003, Current drug metabolism.
[22] Ulrich M. Zanger,et al. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[23] A. Barve,et al. Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats , 1998, Pharmaceutical Research.
[24] W. Hayton. Rate-limiting barriers to intestinal drug absorption: A review , 1980, Journal of Pharmacokinetics and Biopharmaceutics.
[25] M. Fromm,et al. Differential expression and function of CYP2C isoforms in human intestine and liver. , 2003, Pharmacogenetics.
[26] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[27] M. Healy,et al. THEORETICAL MODEL OF GASTROINTESTINAL ABSORPTION OF LEAD , 1984, Journal of clinical and hospital pharmacy.
[28] Denis M. Bayada,et al. Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.
[29] Han van de Waterbeemd,et al. Pharmacokinetics and metabolism in drug design , 2001 .
[30] D. Scott,et al. Pharmacokinetics of lidocaine in man , 1971, Clinical pharmacology and therapeutics.
[31] Chaumeil Jc. Micronization: a method of improving the bioavailability of poorly soluble drugs. , 1998 .
[32] G. L. Kedderis,et al. Sex-dependent metabolism of xenobiotics. , 1998, Drug metabolism reviews.
[33] B. Chauhan,et al. Cyclodextrins: application in different routes of drug administration. , 2005, Acta pharmaceutica.
[34] R. Edwards,et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. , 1996, Biochemical pharmacology.
[35] P. Royall,et al. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. , 1999, International journal of pharmaceutics.
[36] A. Peregrina,et al. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. , 1997, Biopharmaceutics & drug disposition.
[37] B. Springthorpe,et al. Which Hydroxy? Evidence for Species Differences in the Regioselectivity of Glucuronidation in Rat, Dog, and Human in Vitro Systems and Dog in Vivo , 2006, Drug Metabolism and Disposition.
[38] S. Imaoka,et al. A sex-specific form of cytochrome P-450 catalyzing propoxycoumarin O-depropylation and its identity with testosterone 6 beta-hydroxylase in untreated rat livers: reconstitution of the activity with microsomal lipids. , 1988, Journal of biochemistry.
[39] W. Tong,et al. Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.
[40] W. Hauck,et al. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies , 1996, Clinical pharmacology and therapeutics.
[41] L. Benet,et al. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. , 2002, Journal of pharmaceutical sciences.
[42] Ferenc Darvas,et al. In Silico and Ex silico ADME approaches for drug discovery. , 2002, Current topics in medicinal chemistry.
[43] S. Pond,et al. First-Pass Elimination Basic Concepts and Clinical Consequences , 1984, Clinical pharmacokinetics.
[44] G. Amidon,et al. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. , 2002, Advanced drug delivery reviews.
[45] G. Edwards,et al. Animal models for the study of intestinal lymphatic drug transport. , 2001, Advanced drug delivery reviews.
[46] R. Austin,et al. A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.
[47] G. Farrell,et al. Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. , 1998, Biochemical and biophysical research communications.
[48] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[49] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[50] K. Luthman,et al. Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.
[51] W. Curatolo,et al. Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.
[52] J. Lin,et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[53] P. Pfeiffer,et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. , 2006, European journal of cancer.
[54] A. P. Lötter,et al. Kinetic study of the solid-state photolytic degradation of two polymorphic forms of furosemide , 1992 .
[55] Panos Macheras,et al. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. , 2002, European Journal of Pharmaceutical Sciences.
[56] J. Castle,et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[57] J. Gustafsson,et al. Gender differences in rat hepatic CYP2C gene expression--regulation by growth hormone. , 1998, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[58] R. Fontana,et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. , 1999, Gastroenterology.
[59] S. Imaoka,et al. Catalytic specificity of CYP2D isoforms in rat and human. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[60] Colin W Pouton,et al. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[61] G. Kirchner,et al. Intestinal metabolism of cyclosporine A in human heart transplant recipients. , 1998, Transplantation proceedings.
[62] Abu T M Serajuddin,et al. IV-IVC considerations in the development of immediate-release oral dosage form. , 2005, Journal of pharmaceutical sciences.
[63] C. Klaassen,et al. Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[64] A. Boobis,et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.
[65] W. L. Chiou. Effect of ‘unstirred’ water layer in the intestine on the rate and extent of absorption after oral administration , 1994, Biopharmaceutics & drug disposition.
[66] L. Marnett,et al. Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. , 1989, Cancer research.
[67] J. Hakkola,et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. , 1996, Biochemical pharmacology.
[68] Baggot Jd. Clinical pharmacokinetics in veterinary medicine. , 1992 .
[69] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[70] S. S. Davis,et al. Lipid vehicles for intestinal lymphatic drug absorption , 1987, The Journal of pharmacy and pharmacology.
[71] J. Halpert,et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. , 2001, Molecular pharmacology.
[72] W. Charman,et al. The Mucosa of the Small Intestine , 2002, Clinical pharmacokinetics.
[73] G. Frenning,et al. Drug release modeled by dissolution, diffusion, and immobilization. , 2003, International journal of pharmaceutics.
[74] G. Drusano,et al. Sex differences in CYP3A activity using intravenous and oral midazolam , 2006, Clinical pharmacology and therapeutics.
[75] A. Braune,et al. Transformation of flavonoids by intestinal microorganisms. , 2003, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.
[76] Alex Avdeef,et al. Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .
[77] G. B. Smith,et al. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[78] Kristina Luthman,et al. Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.
[79] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[80] Hans Lennernäs,et al. Does Fluid Flow Across the Intestinal Mucosa Affect Quantitative Oral Drug Absorption? Is It Time for a Reevaluation? , 1995, Pharmaceutical Research.
[81] A. Lichtenstein. Intestinal cholesterol metabolism. , 1990, Annals of medicine.
[82] G. Corazza,et al. Measurements of the jejunal unstirred layer in normal subjects and patients with celiac disease. , 1996, The American journal of physiology.
[83] N. Benowitz,et al. Clinical Pharmacokinetics of Lignocaine , 1978, Clinical pharmacokinetics.
[84] P. Toutain,et al. Bioavailability and its assessment. , 2004, Journal of veterinary pharmacology and therapeutics.
[85] Narayanan Surendran,et al. Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. , 2002, Journal of pharmaceutical sciences.
[86] D. Greenblatt,et al. In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[87] M Rowland,et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. , 1998, Journal of pharmaceutical sciences.
[88] K. Inui,et al. Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. , 2003, Drug metabolism and pharmacokinetics.
[89] B. Testa,et al. Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques , 2002, Cellular and Molecular Life Sciences CMLS.
[90] P. Artursson,et al. Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[91] H. Lennernäs,et al. Regional Gastrointestinal Absorption of the Beta-Blocker Pafenolol in the Rat and Intestinal Transit Rate Determined by Movement of 14C-Polyethylene Glycol (PEG) 4000 , 2004, Pharmaceutical Research.
[92] J. Schellens,et al. The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery , 2000, Investigational New Drugs.
[93] Donald C. Monkhouse,et al. Review ArticlePharmaceutical Salts , 1977 .
[94] H. Adlercreutz,et al. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[95] S K Balani,et al. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[96] J. Goldstein,et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.
[97] M. Stromberg,et al. Anatomy and embryology of the laboratory rat , 1986 .
[98] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[99] R. de Kanter,et al. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.
[100] P. van Bladeren,et al. Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. , 2002, Chemical research in toxicology.
[101] D. Smith,et al. Species differences in metabolism and pharmacokinetics: are we close to an understanding? , 1991, Drug metabolism reviews.
[102] E. Hodgson,et al. Metabolism of Endosulfan-α by Human Liver Microsomes and Its Utility as a Simultaneous in Vitro Probe for CYP2B6 and CYP3A4 , 2006, Drug Metabolism and Disposition.
[103] R. Riley,et al. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[104] A. Boobis,et al. Expression and inducibility of P450 enzymes during liver ontogeny , 1997, Microscopy research and technique.
[105] P. Rolan,et al. Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. , 1999, Journal of pharmaceutical sciences.
[106] Lipophilicity and biological acitivity. Drug transport and drug distribution in model systems and in biological systems. , 1979, Arzneimittel-Forschung.
[107] Jaran Eriksen,et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population , 2006, Pharmacogenetics and genomics.
[108] John-Michael Sauer,et al. Clinical Pharmacokinetics of Atomoxetine , 2005, Clinical pharmacokinetics.
[109] S. Sabnis. Factors Influencing the Bioavailability of Peroral Formulations of Drugs for Dogs , 1999, Veterinary Research Communications.
[110] F. Guengerich. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. , 1997, Chemico-biological interactions.
[111] C. Porter,et al. Bile Increases Intestinal Lymphatic Drug Transport in the Fasted Rat , 2005, Pharmaceutical Research.
[112] Kazutaka Higaki,et al. Gastrointestinal transit and drug absorption. , 2000, Biological & pharmaceutical bulletin.
[113] Z T Chowhan,et al. pH-solubility profiles or organic carboxylic acids and their salts. , 1978, Journal of pharmaceutical sciences.
[114] G. Mckay,et al. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase , 2004, European Journal of Clinical Pharmacology.
[115] H. van de Waterbeemd,et al. Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.
[116] H. Yamazaki,et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[117] Aditya Mohan Kaushal,et al. Amorphous drug delivery systems: molecular aspects, design, and performance. , 2004, Critical reviews in therapeutic drug carrier systems.
[118] E NELSON,et al. Solution rate of theophylline salts and effects from oral administration. , 1957, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.
[119] D. Bailey,et al. Grapefruit juice—felodipine interaction: Effect of naringin and 6′,7′‐dihydroxybergamottin in humans , 1998, Clinical pharmacology and therapeutics.
[120] John-Michael Sauer,et al. Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[121] R. Gugler,et al. Effects of Antacids on the Clinical Pharmacokinetics of Drugs , 1990, Clinical pharmacokinetics.
[122] K. Morris,et al. Reactivity differences of indomethacin solid forms with ammonia gas. , 2002, Journal of the American Chemical Society.
[123] G. Macfarlane,et al. Collaborative JPEN‐Clinical Nutrition Scientific Publications Role of intestinal bacteria in nutrient metabolism , 1997 .
[124] R. Kim,et al. Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans , 2007, Clinical pharmacology and therapeutics.
[125] G. Flynn,et al. Solubility of organic hydrochlorides. , 1972, Journal of pharmaceutical sciences.
[126] J. DeSesso,et al. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[127] J. Dressman,et al. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.
[128] D. A. Smith,et al. Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[129] David R. Friend,et al. Drug delivery to the small intestine , 2004, Current gastroenterology reports.
[130] D. Smith,et al. Human cytochrome P450s: selectivity and measurement in vivo. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[131] E. De Clercq,et al. Species-dependent and site-specific intestinal metabolism of ester prodrugs. , 2000, International journal of pharmaceutics.
[132] Ho-Chul Shin,et al. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model , 2006, Pharmaceutical Research.
[133] H. Pols,et al. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. , 2005, The Journal of clinical endocrinology and metabolism.
[134] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[135] J. Lin,et al. Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[136] Christoph Hiemke,et al. Identification of P‐glycoprotein substrates and inhibitors among psychoactive compounds — implications for pharmacokinetics of selected substrates , 2004, The Journal of pharmacy and pharmacology.
[137] K. Midha,et al. Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.
[138] R. Riley,et al. The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting , 2007, Drug Metabolism and Disposition.
[139] Vijay K Gombar,et al. Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. , 2003, Current topics in medicinal chemistry.
[140] P. Sinko,et al. Intestinal drug transporters: in vivo function and clinical importance. , 2004, Current drug metabolism.
[141] E. Nelson. Comparative dissolution rates of weak acids and their sodium salts. , 2006, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.
[142] D W Nebert,et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.
[143] Han van de Waterbeemd,et al. Pharmacokinetics and Metabolism in Drug Design: SMITH: PHARMACOKINETICS AND METABOLISM IN DRUG DESIGN O-BK , 2006 .
[144] R. Eyjólfsson. Enalapril maleate polymorphs: instability of form II in a tablet formulation. , 2002, Die Pharmazie.
[145] Abu T M Serajuddin,et al. Trends in solubility of polymorphs. , 2005, Journal of pharmaceutical sciences.
[146] Karluss Thomas,et al. Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[147] C. Nyström,et al. Coulter Counter measurements of solubility and dissolution rate of sparingly soluble compounds using micellar solutions * , 1986, The Journal of pharmacy and pharmacology.
[148] Han van de Waterbeemd,et al. High-throughput and in silico techniques in drug metabolism and pharmacokinetics. , 2002 .
[149] D W Nebert,et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.
[150] K. Reuhl,et al. Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum , 2003, Archives of Toxicology.
[151] W. S. Snyder,et al. Report of the task group on reference man , 1979, Annals of the ICRP.
[152] D. Winne. Unstirred layer thickness in perfused rat jejunum in vivo , 1976, Experientia.
[153] U. Brinkmann,et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. , 2001, Pharmacogenetics.
[154] R. Strickley. Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.
[155] W. Peters,et al. Cytochromes P-450 in the intestinal mucosa of man. , 1989, Biochemical pharmacology.
[156] Oleg A Raevsky,et al. Physicochemical descriptors in property-based drug design. , 2004, Mini reviews in medicinal chemistry.
[157] T. Cresteil,et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. , 1997, Pharmacogenetics.
[158] W. L. Chiou,et al. Similarity in the linear and non-linear oral absorption of drugs between human and rat. , 2000, International journal of clinical pharmacology and therapeutics.
[159] Honghui Zhou. Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles , 2003, Journal of clinical pharmacology.
[160] J. Dressman,et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.
[161] P. Enck,et al. Stress effects on gastrointestinal transit in the rat. , 1989, Gut.
[162] Kjell Johnson,et al. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. , 2004, International journal of pharmaceutics.
[163] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[164] P. Thomas,et al. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[165] D. Nebert,et al. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. , 1989, Molecular endocrinology.
[166] K. Uekama,et al. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. , 1997, Journal of pharmaceutical sciences.
[167] S. Krämer,et al. Physicochemical properties in pharmacokinetic lead optimization. , 2001, Farmaco.
[168] W. Jaeger,et al. Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.
[169] Shobha Bhattachar,et al. The road map to oral bioavailability: an industrial perspective , 2006, Expert opinion on drug metabolism & toxicology.
[170] G. Gregoriadis,et al. Fat soluble vitamins in liposomes: studies on incorporation efficiency and bile salt induced vesicle disintegration. , 1993, Journal of drug targeting.
[171] P. Enck,et al. Repeated noninvasive measurement of gastrointestinal transit in rats , 1989, Physiology & Behavior.